Harvard Bioscience at Risk of Nasdaq Delisting: Implications for Investors and Business Stability

Harvard Bioscience (HBIO) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Harvard Bioscience faces a significant business risk as it has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, which could lead to delisting. This situation poses a threat to the company’s ability to raise capital, affects the liquidity and market price of its common stock, and could result in a loss of investor confidence. The company has until October 1, 2025, to regain compliance, potentially through a reverse stock split, but there is no guarantee of success. Delisting could also impact employee morale, customer trust, and business development opportunities.

The average HBIO stock price target is $1.75, implying 262.69% upside potential.

To learn more about Harvard Bioscience’s risk factors, click here.